Botanical species · safety record

Sparganium stoloniferum

The EFSA Compendium of Botanicals holds 4 constituent measurements and 1 adverse-effect record for Sparganium stoloniferum. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Sparganium stoloniferum (Buch.-Ham. ex Graebn.) Buch.-Ham. ex Juz.

4Constituent measurements
1Safety records
5Cited sources
1Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 1 licensed products naming Sparganium stoloniferum as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

  • Rhizome

What the records describe

Constituents measured

  • Alkaloids1
  • Coumarins1
  • Phenylpropanoids1
  • Pyridine alkaloids1

Plant parts

  • Roots and other underground parts3
  • Aerial part of plants1
  • Stem1
  • stalk1

Preparations

  • Solvent extraction5

Effect types

  • Reproductive1

Target tissues

  • Muscle, skeletal1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
PhenylpropanoidsRoots and other underground partsSolvent extractionStandard Chromatographic tests (paper- thin layer- and column chromatography)Resolve DOI
Pyridine alkaloidsStem / stalkSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI
AlkaloidsRoots and other underground partsSolvent extraction5.99 PercentNuclear Magnetic Resonance (NMR)No resolvable identifier
CoumarinsAerial part of plantsSolvent extractionHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
ReproductiveMuscle, skeletalRoots and other underground partsSolvent extractionHouse mouse (as animal)Reproduction toxicityResolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Sun, Jie., Wang, Shao., Wei, Ya-Hui. Reproductive toxicity of Rhizoma Sparganii (Sparganium stoloniferum Buch.-Ham.) in mice: Mechanisms of anti-angiogenesis and anti-estrogen pharmacologic activities. JOURNAL OF ETHNOPHARMACOLOGY, 2011, vol. 137, no. 3, p. 1498-1503. DOI
  2. Sun, Jie., Wei, Ya-Hui. A new alkaloid-aluminum glycoside isolated from Rhizoma Sparganii (Sparganium stoloniferum Buch. -Ham.). JOURNAL OF MEDICINAL PLANTS RESEARCH, 2011, vol. 5, no. 14, p. 3128-3131.
  3. Bateman, Henry R., Liang, Qiaoli., Fan, Daping., Rodriguez, Vanessa., Lessner, Susan M. Sparstolonin B inhibits pro-angiogenic functions and blocks cell cycle progression in endothelial cells. Plos one, 2013.
  4. Wu, Hao., Feng, Ruihong., Guan, Shuguang., Yu, Wenbo., Man, Wei., Guo, Jiling., Liu, Xuan., Yang, Min., Jiang, Baohong., Wu, Wanying., Zhang, Lianxue., Guan, Shuhong., Guo, Dean. Rapid preparative isolation of a new phenylpropanoid glycoside and four minor compounds from Sparganium stoloniferum using high-speed counter-current chromatography as a fractionation tool . Journal of separation science, 2012, vol. 35, no. 9, p. 1160-1166. DOI
  5. Li, Shu-Xian., Wang, Feng., Deng, Xiao-Hui., Liang, Sheng-Wang. A new alkaloid from the stem of Sparganium stoloniferum Buch.-Ham. JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH, 2010, vol. 12, no. 4, p. 331-333. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue